The FDA has granted an additional six months of pediatric exclusivity to Pfizer’s (PFE +1.2%) LYRICA (pregabalin), extending the period to June 30, 2019. The agency based its decision on data from the LYRICA Pediatric Epilepsy Program which was submitted at the FDA’s request to evaluate the drug as adjunctive therapy for partial onset seizures in pediatric epilepsy patients.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.